Oncothyreon Inc (ONTY) 2.81 $ONTY
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
Oncothyreon Reports First Quarter 2014 Financial Results
PR Newswire - Thu May 01, 3:05PM CDT
Company to Hold Conference Call at 4:30 p.m. EDT Today
Oncothyreon Announces First Quarter 2014 Financial Results Conference Call
PR Newswire - Thu Apr 24, 7:00AM CDT
Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call on Thursday, May 1, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its first quarter 2014 financial results and provide a review of its pipeline of products in development.
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
Hot Stock: Oncothyreon, Shares Drop 13.4% (ONTY)
Comtex SmarTrend(R) - Tue Apr 15, 11:45AM CDT
Oncothyreon (NASDAQ:ONTY) is one of today's worst performing low-priced stocks, down 13.4% to $2.24 on 1.0x average daily volume. Thus far today, Oncothyreon has traded 933,000 shares, vs. average volume of 922,000 shares per day. The stock has underperformed the Dow (-13.4% to the Dow's -0.4%) and underperformed the S&P 500 (-13.4% to the S&P's -0.4%) during today's trading.
Merck KGaA Starts Study on Tecemotide - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:55PM CDT
Oncothyreon announced that Merck KGaA commenced a phase III study, START2, on oncology candidate, tecemotide (L-BLP25).
Merck Launches Hail Mary Lung Cancer Trial
Catherine Shaffer, The Motley Fool - Motley Fool - Tue Apr 08, 5:30PM CDT
With the launch of its phase 3 START2 study of tecemotide in non-small cell lung cancer, Merck is either advancing a valuable asset, or throwing good money after bad, depending on whether you are a believer in a subgroup analysis of its previously...
Oncothyreon Announces Merck KGaA, Darmstadt, Germany, Initiation of Phase 3 START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer
PR Newswire - Mon Apr 07, 5:00AM CDT
Oncothyreon Inc. (NASDAQ: ONTY) today announced that Merck KGaA, Darmstadt, Germany, has initiated the international Phase 3 START2 study, which is designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC). Merck KGaA, Darmstadt, Germany, is developing tecemotide under a license agreement with Oncothyreon.
Oncothyreon Inc. (ONTY) in Focus: Stock up 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:44AM CDT
Oncothyreon Inc. was a big mover last session, as the company saw its shares rise slightly over 6% on the day.
Top Gainers Technical Data -- Research on First Solar, Oncothyreon, Unilife, and Synthetic Biologics
PR Newswire - Thu Mar 20, 7:07AM CDT
The US markets saw a negative sentiment on Wednesday, March 19, 2014, with the NASDAQ Composite closing at 4,307.60, down 0.59%, the Dow Jones Industrial Average ending the session at 16,222.17, down 0.70% and the S&P 500 edging 0.61% lower to finish the trading session at 1,860.77. The losses were broad based as all the ten sectors ended the session in negative. A number of stocks saw large movements, including First Solar Inc. (NASDAQ: FSLR), Oncothyreon Inc. (NASDAQ: ONTY), Unilife Corp. (NASDAQ: UNIS), and Synthetic Biologics Inc. (AMEX: SYN). Free technical research on FSLR, ONTY, UNIS, and SYN can be downloaded upon signing up at:
Why Oncothyreon, Inc. Shares Sank
Brian Pacampara, The Motley Fool - Motley Fool - Fri Mar 14, 11:43AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of clinical-stage biopharmaceutical company ...
Stock to Watch: Oncothyreon Down 7.3% (ONTY)
Comtex SmarTrend(R) - Fri Mar 14, 10:40AM CDT
Oncothyreon (NASDAQ:ONTY) is one of today's worst performing low-priced stocks, down 7.3% to $3.61 on 1.2x average daily volume. Oncothyreon has traded 1.1 million shares thus far today, vs. average volume of 904,000 shares per day. The stock has underperformed the Dow (-7.3% to the Dow's -0.2%) and underperformed the S&P 500 (-7.3% to the S&P's -0.2%) during today's trading.
Downgrade Alert for Oncothyreon (ONTY)
Comtex SmarTrend(R) - Fri Mar 14, 6:57AM CDT
Oncothyreon (NASDAQ:ONTY) was downgraded from Buy to Hold at Cantor today. The stock closed yesterday at $3.89 on volume of 2.1 million shares, above average daily volume of 904,000. Oncothyreon share prices have moved between a 52-week high of $11.59 and a 52-week low of $1.55 and closed yesterday at 151% above that low price at $3.89 per share. Over the last five market days, the 200-day moving average (MA) has gone up 1.8% while the 50-day MA has advanced 6.6%.
Oncothyreon Reports Full Year and Fourth Quarter 2013 Financial Results
PR Newswire - Thu Mar 13, 3:01PM CDT
Company to Hold Conference Call at 4:30 p.m. EDT Today
Oncothyreon (ONTY) Jumps: Stock Moves 9.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:46AM CST
Oncothyreon was a big mover last session, as the company saw its shares rise nearly 10% on the day.
Oncothyreon Announces Full Year and Fourth Quarter 2013 Financial Results Conference Call
PR Newswire - Thu Mar 06, 7:00AM CST
Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call on Thursday, March 13, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its full year and fourth quarter 2013 financial results and provide a review of its pipeline of products in development.
Hot Stock: Oncothyreon, Shares Gain 5.4% (ONTY)
Comtex SmarTrend(R) - Wed Mar 05, 12:45PM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 5.4% to $3.41 on 1.3x average daily volume. Thus far today, Oncothyreon has traded 1.2 million shares, vs. average volume of 899,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's -0.2%) and outperformed the S&P 500 (5.4% to the S&P's 0.0%) during today's trading.
Oncothyreon to Present at Cowen and Company 34th Annual Health Care Conference
PR Newswire - Wed Feb 26, 7:00AM CST
Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Cowen and Company 34th Annual Health Care Conference in Boston on Wednesday, March 5, 2014 at 9:20 a.m. Eastern.
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
Oncothyreon Reports First Quarter 2014 Financial Results
PR Newswire - Thu May 01, 3:05PM CDT
Company to Hold Conference Call at 4:30 p.m. EDT Today
Oncothyreon Announces First Quarter 2014 Financial Results Conference Call
PR Newswire - Thu Apr 24, 7:00AM CDT
Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call on Thursday, May 1, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its first quarter 2014 financial results and provide a review of its pipeline of products in development.
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
Hot Stock: Oncothyreon, Shares Drop 13.4% (ONTY)
Comtex SmarTrend(R) - Tue Apr 15, 11:45AM CDT
Oncothyreon (NASDAQ:ONTY) is one of today's worst performing low-priced stocks, down 13.4% to $2.24 on 1.0x average daily volume. Thus far today, Oncothyreon has traded 933,000 shares, vs. average volume of 922,000 shares per day. The stock has underperformed the Dow (-13.4% to the Dow's -0.4%) and underperformed the S&P 500 (-13.4% to the S&P's -0.4%) during today's trading.
Merck KGaA Starts Study on Tecemotide - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:55PM CDT
Oncothyreon announced that Merck KGaA commenced a phase III study, START2, on oncology candidate, tecemotide (L-BLP25).
Merck Launches Hail Mary Lung Cancer Trial
Catherine Shaffer, The Motley Fool - Motley Fool - Tue Apr 08, 5:30PM CDT
With the launch of its phase 3 START2 study of tecemotide in non-small cell lung cancer, Merck is either advancing a valuable asset, or throwing good money after bad, depending on whether you are a believer in a subgroup analysis of its previously...
Oncothyreon Announces Merck KGaA, Darmstadt, Germany, Initiation of Phase 3 START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer
PR Newswire - Mon Apr 07, 5:00AM CDT
Oncothyreon Inc. (NASDAQ: ONTY) today announced that Merck KGaA, Darmstadt, Germany, has initiated the international Phase 3 START2 study, which is designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC). Merck KGaA, Darmstadt, Germany, is developing tecemotide under a license agreement with Oncothyreon.
Oncothyreon Inc. (ONTY) in Focus: Stock up 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:44AM CDT
Oncothyreon Inc. was a big mover last session, as the company saw its shares rise slightly over 6% on the day.
Top Gainers Technical Data -- Research on First Solar, Oncothyreon, Unilife, and Synthetic Biologics
PR Newswire - Thu Mar 20, 7:07AM CDT
The US markets saw a negative sentiment on Wednesday, March 19, 2014, with the NASDAQ Composite closing at 4,307.60, down 0.59%, the Dow Jones Industrial Average ending the session at 16,222.17, down 0.70% and the S&P 500 edging 0.61% lower to finish the trading session at 1,860.77. The losses were broad based as all the ten sectors ended the session in negative. A number of stocks saw large movements, including First Solar Inc. (NASDAQ: FSLR), Oncothyreon Inc. (NASDAQ: ONTY), Unilife Corp. (NASDAQ: UNIS), and Synthetic Biologics Inc. (AMEX: SYN). Free technical research on FSLR, ONTY, UNIS, and SYN can be downloaded upon signing up at:
Why Oncothyreon, Inc. Shares Sank
Brian Pacampara, The Motley Fool - Motley Fool - Fri Mar 14, 11:43AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of clinical-stage biopharmaceutical company ...
Stock to Watch: Oncothyreon Down 7.3% (ONTY)
Comtex SmarTrend(R) - Fri Mar 14, 10:40AM CDT
Oncothyreon (NASDAQ:ONTY) is one of today's worst performing low-priced stocks, down 7.3% to $3.61 on 1.2x average daily volume. Oncothyreon has traded 1.1 million shares thus far today, vs. average volume of 904,000 shares per day. The stock has underperformed the Dow (-7.3% to the Dow's -0.2%) and underperformed the S&P 500 (-7.3% to the S&P's -0.2%) during today's trading.
Downgrade Alert for Oncothyreon (ONTY)
Comtex SmarTrend(R) - Fri Mar 14, 6:57AM CDT
Oncothyreon (NASDAQ:ONTY) was downgraded from Buy to Hold at Cantor today. The stock closed yesterday at $3.89 on volume of 2.1 million shares, above average daily volume of 904,000. Oncothyreon share prices have moved between a 52-week high of $11.59 and a 52-week low of $1.55 and closed yesterday at 151% above that low price at $3.89 per share. Over the last five market days, the 200-day moving average (MA) has gone up 1.8% while the 50-day MA has advanced 6.6%.
Oncothyreon Reports Full Year and Fourth Quarter 2013 Financial Results
PR Newswire - Thu Mar 13, 3:01PM CDT
Company to Hold Conference Call at 4:30 p.m. EDT Today
Oncothyreon (ONTY) Jumps: Stock Moves 9.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:46AM CST
Oncothyreon was a big mover last session, as the company saw its shares rise nearly 10% on the day.
Oncothyreon Announces Full Year and Fourth Quarter 2013 Financial Results Conference Call
PR Newswire - Thu Mar 06, 7:00AM CST
Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call on Thursday, March 13, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its full year and fourth quarter 2013 financial results and provide a review of its pipeline of products in development.
Hot Stock: Oncothyreon, Shares Gain 5.4% (ONTY)
Comtex SmarTrend(R) - Wed Mar 05, 12:45PM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 5.4% to $3.41 on 1.3x average daily volume. Thus far today, Oncothyreon has traded 1.2 million shares, vs. average volume of 899,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's -0.2%) and outperformed the S&P 500 (5.4% to the S&P's 0.0%) during today's trading.
Oncothyreon to Present at Cowen and Company 34th Annual Health Care Conference
PR Newswire - Wed Feb 26, 7:00AM CST
Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Cowen and Company 34th Annual Health Care Conference in Boston on Wednesday, March 5, 2014 at 9:20 a.m. Eastern.
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
